$ICL

ICL Group Ltd. $ICL is Y.D. More Investments Ltd's 5th Largest Position

Y.D. More Investments Ltd increased its stake in ICL Group Ltd. (ICL) by 5.5% in Q4, making it their 5th largest holding, valued at $107.5 million. ICL reported Q4 EPS in line with estimates at $0.09 but missed revenue forecasts at $1.70 billion, while analysts maintain a "Hold" rating with an average price target of $6.10. The company currently trades near $5.24, has a market cap of $6.76 billion, and offers an annualized dividend of $0.19, yielding approximately 3.6%.

Original reporting
MarketBeat · MarketBeat
Published Apr 6, 2026, 12:38 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 6, 2026, 1:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ICL Group Ltd. $ICL is Y.D. More Investments Ltd's 5th Largest Position — source image
Decision brief

The 30-second read

$ICLNeutralMed
01

Why it matters

The increased institutional stake indicates confidence, but revenue miss introduces uncertainty. The stock's current valuation near support levels offers potential entry points for patient investors.

02

Market read

The news highlights institutional confidence in ICL amidst mixed earnings results, influencing short-term trading sentiment.

03

What to watch

Potential for a rebound if the stock finds support at current levels and if sector conditions improve.

Timing: short-term (next 1-3 weeks)

Background

ICL is a major player in the specialty minerals and chemicals sector, with recent earnings in line with estimates but missing revenue forecasts, which may impact investor sentiment.

Company-level read

Ticker impact

$ICLNeutralMedium confidence
Context

Primary focus due to increased stake and recent earnings report.

Expected impact

Potential short-term stabilization or slight decline due to revenue miss, but long-term outlook remains uncertain.

Evidence & confidence

The increased institutional stake suggests confidence, but revenue miss and valuation near support levels introduce caution.

Market effects

Potential positive sentiment in the chemical and specialty materials sector due to increased institutional confidence.

Limited; primarily affecting investor sentiment in regions where ICL operates.

Moderate; reflects ongoing institutional interest and earnings performance in the sector.

Counterpoint

The revenue miss could signal deeper issues, suggesting caution against increasing exposure.

Key entities

  • ICL Group Ltd

    A global specialty minerals and chemicals company.

  • Y.D. More Investments Ltd

    An investment firm increasing its stake in ICL.

Related articles

$ICLMed

ICL reports Q2 2026 sales higher by 17% to $2.1 billion

ICL reported Q2 2026 sales of $2.1 billion, up 17% from $1.8 billion a year earlier, citing stronger pricing and demand. Operating income rose to $266 million from $181 million, and net income to $137 million from $93 million. Adjusted EBITDA was $448 million. ICL reiterated FY2026 adjusted EBITDA guidance of $1.5 billion to $1.7 billion and potash volumes of 4.5 to 4.7 million metric tons.

$ICLMedAI 8/10

ICL (ICL) Q2 2026 Earnings Call Transcript

ICL Group reported Q2 2026 sales of $2.1 billion, up 17%, and adjusted EBITDA of $448 million, up 28%, citing higher potash, bromine and phosphate prices. Adjusted net income rose 35% to $149 million, and adjusted EPS rose 33% to $0.12. Free cash flow was $94 million. Full-year 2026 EBITDA guidance was reiterated at $1.5 billion to $1.7 billion.

$ICLMedAI 8/10

ICL Group LTD: ICL Reports Second Quarter 2026 Results

ICL Group (NYSE: ICL) reported Q2 2026 results for the quarter ended June 30, 2026. Consolidated sales rose to $2.1 billion (+17% Y/Y). Operating income increased to $266 million from $181 million, and net income attributable to shareholders rose to $137 million from $93 million. ICL reiterated FY2026 adjusted EBITDA guidance of $1.5B to $1.7B and expects potash volumes of 4.5 to 4.7 million metric tons.

$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).